Communication
Truncated Reverse Isoxazolidinyl Nucleosides: A New Class of Allosteric HIV-1 Reverse Transcriptase Inhibitors
Article first published online: 9 FEB 2012
DOI: 10.1002/cmdc.201200022
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Additional Information
How to Cite
Romeo, R., Giofrè, S. V., Macchi, B., Balestrieri, E., Mastino, A., Merino, P., Carnovale, C., Romeo, G. and Chiacchio, U. (2012), Truncated Reverse Isoxazolidinyl Nucleosides: A New Class of Allosteric HIV-1 Reverse Transcriptase Inhibitors. ChemMedChem, 7: 565–569. doi: 10.1002/cmdc.201200022
Publication History
- Issue published online: 27 MAR 2012
- Article first published online: 9 FEB 2012
- Manuscript Received: 12 JAN 2012
Funded by
- Italian Ministry of Education, Universities, and Research (MIUR)
- University of Messina (Italy)
- University of Catania (Italy)
- Interuniversity Consortium for Innovative Methodologies and Processes for Synthesis (CINMPIS), the University of Milan–Bicocca (Italy)
Keywords:
- docking studies;
- HIV-1;
- noncompetitive inhibitors;
- pyrimidinyl isoxazolidines;
- reverse transcriptases

Affairs of the HAART! The synthesis of HEPT-derived, truncated reverse isoxazolidinyl nucleosides (shown) is reported. These compounds represent the first examples of isoxazolidines bearing a pyrimidine scaffold at the C-3 position using a glycoside-type linkage. Biological evaluation showed that some of the derivatives act as non-nucleoside inhibitors of HIV-1 reverse transcriptase, with an efficacy comparable to that of Nevirapine but with reduced toxicity.

1860-7187/asset/2452_left.gif?v=1&s=4110e7425ac5e40773dfb0778cfefa62f1594507)
1860-7187/asset/2452_right.gif?v=1&s=8458ea1f15af84217b579501ed7d7733bef04a94)
